This insider cluster is routine and non-informative. The EVP's sale is a standard exercise-and-cover pattern with no bearish signal. Monitor for any material news (e.g., FDA decision on aficamten, upcoming earnings) that could drive the stock, but this filing itself provides no trading edge.
CYTK drugs
CYTK drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+20- T+0 · Sep 14 $72.45entry
- T+1 · 2mo ago −4.33%α −3.88% · $69.31
- T+5 · 8w ago −6.75%α −6.86% · $67.56
- T+20 · 5w ago −13.33%α −15.60% · $62.79
- T+45 · todayOpen
- T+60 · in 21d Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Two insiders at Cytokinetics sold a combined $339K in open-market sales over a week. The EVP of R&D exercised and immediately sold option shares, a classic tax-covering pattern, while a director made a small sale. At a $10.2B market cap, these sales represent ~0.003% of market cap, trivial and routine, not indicative of bearish conviction.
Key Financial Metrics
Key Facts
- EVP R&D Malik Fady Ibraham exercised 3,500 options at $7.80/share and immediately sold 3,500 shares at $75.46 for $264K, a routine exercise-and-sell pattern to cover tax obligations.
- Director Robert E. Landry sold 1,000 shares at $74.66 for $75K, a very small position reduction.
- Total open-market sales of $339K represent ~0.003% of CYTK's $10.2B market cap, far below the 0.1% materiality threshold.
- No open-market purchases were made by any insider in this cluster.
Financial Impact
Total insider sales of $339K, or ~0.003% of market cap, immaterial.
Risk Factors
- Insider sales, while small, could be misinterpreted by retail as bearish.
- Cytokinetics is a binary-risk biotech, any negative regulatory or clinical news would overwhelm this trivial insider activity.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-CYTK-1789168927236 |
Track record
46 reports on CYTK
7 of 11 bullish or bearish reports moved the stock their way by T+20. Best: +8.59% at T+20 after the Sep 15, 2026 report. 10 of 11 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $53.76 Now $56.13 +4.41% settles Dec 15
- Nov 12, 20264d ago Insider Cluster Neutral 3/10 Entry $56.13 Now $56.13 +0.00% settles Dec 14
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $56.18 Now $56.13 −0.09% settles Dec 9
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $56.18 Now $56.13 −0.09% settles Dec 9
- Nov 9, 20267d ago Institutional Cluster Neutral 3/10 Entry $55.14 Now $56.13 +1.80% settles Dec 8
- Nov 9, 20267d ago Press Release Neutral 4/10 Entry $55.14 Now $56.13 +1.80% settles Dec 8
- Nov 4, 202612d ago 8-K Bullish 6/10 No price data
- Nov 4, 202612d ago Press Release Neutral 5/10 Entry $55.55 Now $56.13 +1.04% settles Dec 4
- Nov 3, 202613d ago Insider Cluster Neutral 2/10 Entry $63.60 Now $56.13 −11.75% settles Dec 3
- Nov 2, 202614d ago Press Release Neutral 3/10 Entry $62.03 Now $56.13 −9.51% settles Dec 1
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers